Index

• Peptone: finding opportunity in disorder
• All Pregnant Women Should Be Screened for Blood-Pressure Disorders, U.S. Advisers Say
• Equip nabs additional investment to expand virtual eating disorder treatment services to adult patients
• Neumora Therapeutics Announces Pricing of Initial Public Offering
• Owkin and Tribun Health Launch Strategic Partnership to Accelerate Access to AI Solutions for Diagnosis and Pharma Research
• Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201 in Relapsed, Refractory T-ALL/T-LL
• Eleos Health and KCare Join Forces to Improve Clinician Support with CareOps Automation
• Substance-use treatment startup Better Life Partners completes $26.5M Series B fundraise
• Comanche Biopharma Named by Fierce Biotech as a “Fierce 15” Biotech Company of 2023
• Comanche Biopharma Receives US FDA Fast Track Designation for CBP-4888 for the Treatment of sFlt-1 mediated pre-term preeclampsia
• Firefly grows in wake of healthcare disruptions in southeastern Mass.
• Madaket Health Releases Provider Data Exchange to Help Payers Remain Compliant with the No Surprises Act
• TraceLink Collaborates with GS1 US to Author GS1 US Addendum Guidance and XML Examples for GS1 US DSCSA Implementation Guideline R1.3 to Support EPCIS Data Exchange
• Innovent Announces the NMPA Approval of SINTBILO® (Tafolecimab Injection) for the Treatment of Adult Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia
• Radiopharmaceuticals for cancer: Making radiation precise
• Health Plan Alliance Selects 1upHealth as Preferred Health Data Interoperability Partner
• Memorial Hermann Health System Makes a Strategic Investment in Capital Rx Customer Solutions Platform
• SoftBank-backed Proximie launches virtual robotic-assisted surgery training course
• Talkiatry and NOCD Team up to Strengthen OCD Care Journeys
• Simon Data Raises Series D Funding Round to Further Develop World’s First Fully-Connected CDP
• Better Life Partners Lands $26.5M for Virtual SUD, Mental Health Platform
• Avalyn Pharma Expands Executive Team with Appointment of Howard M. Lazarus, MD, FCCP to the Role of Chief Medical Officer
• Talkiatry, NOCD Strike Partnership To Support Patients With OCD
• Born out of Omega push for pandemic treatments, Aerium Therapeutics enters long Covid R&D
• With ISO certification, Owkin demonstrates commitment to utmost quality with its AI solutions for digital pathology
• Sironax Announces Closing of $200 Million Series B Financing
• Member Spotlight: F-Prime Capital
• Avalyn Pharma Invited to Present at Canaccord Genuity Annual Growth Conference
• Patina teams with Humana to expand reach of convenient, relationship-centered primary care for people with Medicare
• Invetx Completes Development of Canine and Feline Half-Life Extension Technology Platform that Significantly Extends Duration of Monoclonal Antibody Treatment Effect
• VR helps brain tumor patients overcome “scanxiety” before brain scans, study finds
• Bicara Therapeutics Expands Management Team with the Appointment of David Raben, M.D., as Chief Medical Officer
• ARTBIO and SpectronRx Enter a Collaboration to Manufacture Key Components of ARTBIO’s AlphaDirect™ Technology
• AppliedVR and National Cancer Institute Collaborate on Research Evaluating Virtual Reality for Reducing Anxiety in Primary Brain Tumor Patients During Imaging Services
• Centivo Launches Partnership with SSM Health
• Tenpoint Therapeutics launches with $70M to restore vision with stem cell therapies and ‘reprogramming’ medicines
• NodThera is first to demonstrate reduction in neuroinflammation in the clinic with brain penetrant NLRP3 inflammasome inhibitor
• Zus Health Joins Civitas Networks for Health
• Patina brings innovative primary care for people 65+ to Charlotte region; designed to help individuals thrive & remain independent
• Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
• Centivo Launches Partnership with SSM Health in the Fond du Lac Market to Offer Wisconsin Businesses and Employees More Affordable, High-Quality Healthcare
• China NMPA approves RareStone’s pitolisant (Wakix) for the treatment of narcolepsy
• Skyline Therapeutics Receives FDA Clearance of IND for SKG0106, a Novel Intravitreally Delivered AAV Gene Therapy Candidate for Neovascular Age-related Macular Degeneration
• Innovent and IASO Bio Announce the NMPA Approval of FUCASO®, the First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed or Refractory Multiple Myeloma
• F-Prime’s Ketan Patel on ‘reverse ageism’ in biotech and investing in a downturn
• K36 Therapeutics raises $70M in Series B to fund multiple myeloma research
• K36 Therapeutics Announces $70 Million Series B Financing to Fund Clinical Proof of Concept of KTX-1001, First-in-class Inhibitor of MMSET for Treatment of Multiple Myeloma Patients with Genetic Translocation (4;14)
• Menopause care is still a largely untapped market. Here’s why investors and startups should dive in
• First AI-generated drug enters human clinical trials, targeting chronic lung disease patients
• Biotech begins human trials of drug designed by artificial intelligence
• First Drug Discovered and Designed with Generative AI Enters Phase II Trials, with First Patients Dosed
• Harvard Medical School, RareCyte developing multiplex imaging for clinical pathology
• Invetx Appoints Dr. Marcus Remmers, Novo Holdings Partner and Animal Health Industry Leader, to Board of Directors
• Castor Appoints New CFO to Drive Transformative Growth
• Innovent and RemeGen Enter into Clinical Trial Collaboration Investigating Combination Therapy of TYVYT® (sintilimab injection) and Novel ADC Candidates for Advanced Solid Tumors in China
• TIME100 Most Influential Companies 2023: Equip
• Precision BioSciences Announces Oral Presentation of Positive ARCUS® Gene Editing Data at International Liver Congress 2023
• ARTBIO: manufacturing strategy to lead on lead-212 radiotherapies
• Ultragenyx opens new gene therapy manufacturing site in Massachusetts
• ARTBIO Launches to Develop New Class of Alpha Radioligand Therapies Designed to Maximize Therapeutic Potential
• ARTBIO emerges with $23M to make radioligand therapies for prostate cancer, with field still in ‘early days’
• WelbeHealth’s Michael Le On The Future Of Innovative At-Home Care Models
• Silver Cross Hospital Expands Use of Kyruus’ Award-Winning Online Scheduling Solution Across Specialties and Services
• India’s Enzene Biosciences unveils $50M New Jersey plant project, plans to hire 300
• Equip Names Nikia Bergan as the Company’s First President
• Equip taps healthcare exec Nikia Bergan as new president to scale up virtual eating disorder treatment services
• Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome)
• NodThera announces positive first-in-human data for two brain penetrant NLRP3 inflammasome inhibitors
• Doceree launches industry-first HCP-focused global DSP for media agencies at Cannes Lions 2023
• With $50M Investment in MOSAIC Project, Owkin Seeks to Become Cancer ‘Drug Discovery Enterprise’
• Eleos Health Partners with Trilogy, Adds COO to Customer Advisory Board
• Owkin Rolls Out Its Landmark AI Diagnostic Within Medipath, the Largest Network of Pathologists in France
• Wedgewood Pharmacy Merges with Blue Rabbit to Deliver Exceptional Veterinary Pharmacy Services Nationwide
• BHB Value: The Pursuit of High Quality Applied Behavior Analysis
• Comanche Biopharma Strengthens Board of Directors with Appointment of Dr. Ann Taylor
• Albert Invent Raises $7.5 Million Seed, Led by Index Ventures, to Bring New Products to Market Faster Than Ever Before
• Game-changing pan-TEAD inhibitor for solid tumours
• The fertility business is booming as startups go after big profits in a $54 billion market, even as other healthcare companies slump
• Pulmocide Announces Expansion of Management Team
• Equip Partnership Adds Eating Disorder Support to Accolade’s Trusted Partner Ecosystem
• Pregnant and over 40? You aren’t alone. More women are becoming later-in-life moms.
• Benchling Delivers an Integrated R&D Ecosystem with New Product Offerings
• Early data show Bicara’s bispecific helps shrink head and neck cancers when combined with Keytruda: #ASCO23
• Bicara Therapeutics’ First-in-class Bifunctional EGFR/TGF-β Inhibitor, BCA101, Demonstrates 65% ORR in Combination with Pembrolizumab in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
• Insilico Medicine describes new USP1 inhibitors for cancer
• Long-term optimism, but short-term worry among Mass. biotech VCs
• PlasmaGen Biosciences to invest in Karnataka for advanced blood plasma production unit
• WelbeHealth Continues Los Angeles Expansion With Opening of New PACE Centers in Rosemead and North Hollywood
• Insilico Medicine divulges new 3CLpro inhibitors for SARS-CoV-2
• TraceLink Ensures DSCSA Verification Readiness and End-to-End VRS Support for Pharmaceutical Supply Chain Members Amid Vendor Turbulence